Patient-reported outcomes and CBPM monitoring.
Neutral by design.
CannaBias helps medical cannabis clinics and healthcare partners understand how prescribed CBPMs perform at a product and batch level, without crossing UK promotional rules. Verified patient-reported experience data supports clinical expectation-setting, batch monitoring, and service improvement, without changing prescribing autonomy or requiring new clinical infrastructure.
Register your interestWhy partner with CannaBias
Stay compliant
Patient-led, non-promotional content designed within UK POM advertising rules and ASA/CAP guidance. Sensitive CBPM product detail is gated to verified prescribed patients only.
Monitor product and batch safety
Track anonymised, aggregated patient-reported signals across producers, products, and batches to identify tolerability patterns and safety trends early.
Reduce callbacks and improve triage
Identify recurring issues — batch inconsistency, supply problems, tolerance — before they reach clinical review cycles. Set realistic expectations early and improve patient satisfaction.
Real-time patient-reported insight
Understand which prescribed cannabis products are trending in patient-reported experience data before your internal monitoring cycles catch up, using aggregated, anonymised insight.
Lightweight to adopt
We work with you to design the parameters to collect, process and present data through our secure ALCOAA+ interface. Designed as modular infrastructure, it's quickly learned and quicker to deploy.
Proven governance, lower risk
Our patient verification process, moderation framework, and UK GDPR data handling reduce governance risk and demonstrate a credible commitment to a transparent, evidence-led CBPM landscape.
Safety, anonymity and security by design
Patient safety & moderation
Gated sensitive info
Detailed CBPM product and batch information is restricted to verified prescribed patients only, in line with UK rules on prescription-only medicine communication.
No medical advice
CannaBias surfaces patient-reported experience only. Moderation actively removes dosage instructions, curative claims, and clinical advice to ensure compliance with MHRA standards.
Report & remove
Our defined moderation processes not only establish a clear pathway for identifying platform misuse, but also enable the swift reporting of content before publication.
Designed for the UK landscape
Neutral & non-promotional
Designed to operate fully within UK POM advertising rules, ASA/CAP guidance, and MHRA communication standards, while remaining genuinely useful to patients and clinics.
Privacy-first
Explicit consent under UK GDPR Articles 6 and 9, data minimisation principles, AES-256 encryption, and defined retention and deletion policies. Patients retain full control of their data.
Clinical reality
We know products change hands across multiple organisations & geographies, often covering several continents before the hands of patients. Our batch view reflects that complexity.
We're here to help clinics and patients, not to hype products. Independent without bias. We are CannaBias.
FAQs for partners
Partner with CannaBias
If you run a UK medical cannabis clinic or healthcare organisation and want structured patient insight and monitoring, let's connect.
Register your interestCannaBias is a public, non-transactional platform. No medical advice. No sales. UK-first.